VLP Therapeutics, LLC. announced today that it has received a grant for approximately US$960,000 from the Global Health Innovative Technology Fund (“the GHIT Fund”) for early-stage research to develop new vaccines for dengue fever using virus-like particles that would target all four strains of the virus. Dengue fever is one of the world’s most serious public health problems, threatening more than half the world’s population, and infecting 50 to 100 million people every year.
PlantVax, Inc. has been contracted by a tier one US defense contractor as the primary supplier of Recombinant Human Acetylcholinesterase (AChE) in support of a Program of Record chemical warfare disclosure spray. The disclosure spray is a first-of-its-kind plant derived enzyme-based sensor that users apply to wide surfaces, enabling rapid visual indication of chemical warfare agents. The spray requires the high expression and stability levels in the AChE that PlantVax specializes in providing. The end product is the first product of its kind that is able to utilize a recombinant, plant-expressed AChE.
Immunomic Therapeutics, Inc. (ITI) and Nature Technology Corporation (NTC) announce today that they have entered into a new license agreement. The licensing of NTC’s RNA-OUT™ and HyperGro™ technology is part of ITI’s expansion into developing nucleic acid immunotherapies for cancer.
ITI believes that LAMP-Vax immunotherapy platform has the potential to transform nucleic acid vaccine therapy. Although additional studies are needed to confirm clinical benefit, LAMP-Vax has the potential to specifically direct the cancer antigen into a processing part of the cell for more efficient presentation to the immune system. Last year, this approach gained important commercial validation when Immunomic Therapeutics entered into significant licensing agreements with Astellas Pharma Inc., totaling over $315 million in upfront payments, as well as potential future milestones and royalty payments.
The Department of Health and Human Services has awarded Emergent BioSolutions a five-year, $198.7 million contract to further mature the development of an anthrax vaccine in preparation for a Food and Drug Administration license.
The HHS office of the assistant secretary for preparedness and response’s Biomedical Advanced Research and Development Authority and Emergent BioSolutions will work to validate the effect of the vaccine candidate NuThrax and verify its safety as part of the contract, HHS said Friday.
AstraZeneca’s global biologics research and development arm MedImmune has entered into a licensing agreement with Allergan for the global rights to MEDI2070, which is currently in a Phase IIb clinical trial for moderate-to-severe Crohn’s disease and ready for Phase II for ulcerative colitis. Under the terms of the deal, Allergan will make an upfront payment to AstraZeneca of $250m for the exclusive, worldwide licence to develop and commercialise the drug.
This month, we talk with David Narrow, chief operating officer of Baltimore startup Sonavex, which is developing a patent-pending, ultrasound-based system that pinpoints potential postsurgical blood clots.
Narrow started developing EchoSure, Sonavex’s ultrasound system, with Devin O’Brien Coon in 2012, when they were both in their first semester of Johns Hopkins’ biomedical engineering graduate program at the Center for Bioengineering Innovation and Design.
As a not-for-profit corporation that manages federally funded research and development centers for the government, MITRE is an ideal organization to host challenges. We do not market or manufacture goods and have no financial investment in the results. Our goal is to work with industry, academia, and government to find solutions that benefit all stakeholders and provide our federal sponsors with the capabilities they need to be successful in their missions.
Working across a wide range of government agencies gives MITRE a broad view into the challenges these agencies face, including the challenges that agencies share. We select our Challenge topics on the basis of this knowledge, looking for gaps that need to be filled.
The National Science Foundation awarded a $3.45 million grant to the University of Maryland to expand research as part of the NSF’s innovation program, said university Associate Vice President for Innovation and Entrepreneurship, Dean Chang.
The grant, part of the NSF’s I-Corps Nodes program, is intended to promote the growth of research and entrepreneurship so that it may be applied on a larger scale, said Chang, the grant’s recipient. The grant is slated to go into effect in the beginning of 2017, Chang said.
Suburban Maryland’s tech cluster is among the top 10 biotech regions in the U.S, ranking at No. 6 based on talent, funding availability and its real estate, according to a new report from real estate brokerage JLL.
“The region is the healthiest it has been in about a decade because of tenant growth, number of life sciences companies, mergers and acquisitions, a lowering vacancy rate and rising rental rates,” said Pete Briskman, a managing director in JLL’s Bethesda office. “However, that could also mean fewer opportunities in the future.”
Under Armour is partnering with a California tech company to provide more people with access to nearby fitness classes nationwide directly through the MyFitnessPal application.
Through the partnership with San Luis Obispo, Calif.-based Mindbody Inc., millions of MyFitnessPal users in the U.S. will be able to search, book and pay for classes at tens of thousands of fitness studios in the Mindbody network. Classes include indoor cycling, martial arts, boxing and yoga.
Mark Cuban has had a bumpy relationship with the healthcare community, but his approach seems to be evolving with a recent step into the world of healthcare venture capital.
According to Inc., the Shark Tank host is the latest to note the issues with healthcare’s middlemen, and has decided to do something about the problem by specifically targeting pharmacies. Cuban describes his vision as a world without the Main Street staple of modern healthcare delivery, predicting that “over the next 15 to 20 years, medicine will be so personalized there will be no drugstores.”
BioBuzz and Elite Sponsor the Institute for Bioscience and Biotechnology Research (IBBR) are excited to announce a special event that lands right in the middle of the Oktoberfest season. Flying Dog Brewery will be our guest as we bring together the worlds of biotech and beer to show how closely related they really are. We are proud to have BioBuzz Double Helix Sponsors CRB and BREP along with Azzur IT as Co-Sponsors for this event.
Before the general networking begins, Flying Dog CEO, Jim Caruso, and COO/Head Brew Master, Matt Brophy will be on the IBBR Auditorium stage from 5:00 p.m. – 6:00 p.m. to speak about the company and everything that goes into the process of brewing their beer.
Wed, Oct 26, 2016 at 5:30 PM – Columbus Center 701 East Pratt Street Baltimore, MD
1st Pitch Life Science is coming to Baltimore for the first time. Hear what happens AFTER a start-up company presents to an investor group! Usually after a pitch, the investors have a closed-door discussion to decide whether the opportunity merits further investigation and possible investment. 1st Pitch Life Science (http://www.1stpitchlifescience.com) offers presenters and audience members the chance to hear what happens in those closed-door discussions, and to learn what really matters to investors.
Chief technologist at the United States Small Business Administration doesn’t immediately sound like the most exciting title, which is part of why after three years, G. Nagesh Rao prefers to be known as the Geek In Residence. He’s responsible for coordinating and leading programs to boost entrepreneurship via the SBA and in partnership across nearly a dozen federal agencies as with the Small Business Innovation Research program. But Rao ranges far beyond just his job. He’s an advisor for half a dozen entrepreneurship related groups including local organizations like Village Capital and LAUNCH, a group jointly run by Nike and a handful of federal agencies.
As midterm season reigns on, Howard University’s administration still has one question left to answer: when exactly is its upcoming tech incubator opening?
At the beginning of the school year, those close to the project said they would be opening the incubator in fall 2016. Now, as of Wednesday, that date has been revised; the incubator won’t open until at least early 2017.
Although progress has been made, there is no denying the biotech industry continues to have a large gender gap. Women hold only 16 percent of the senior management posts at the top pharma companies, and of senior executive positions at emerging companies — the 10 companies that raised most in venture capital A rounds in 2014 — only 12 (17 percent) were filled by women.*
Accelerate Baltimore, Emerging Technology Centers’ seed accelerator program, landed $250,000 from the Abell Foundation to help fund its sixth year.
The four-month accelerator program gives each participating company $25,000 in seed funding, free office space, access to an advisory team, instructional programming, mentors and connections to potential investors. The program ends with a Demo Day, attended by angel investors and venture capitalists.
The Center for Innovative Technology (CIT) announced today the Commonwealth Research Commercialization Fund (CRCF) Request for Proposals (RFP) for FY2017. The solicitation opens today and Letters of Intent (LOIs) are due by Thursday, November 10th. Award announcements are planned for early June 2017.
The CRCF grows Virginia’s economy by supporting high-potential technology commercialization projects at Virginia’s public and private colleges and universities, the private sector and nonprofit research institutions. A single solicitation for $2.8 million will be offered in FY2017, with five programs available for funding: Commercialization, SBIR Matching Funds, STTR Matching Funds, Matching Funds and Eminent Researcher Recruitment.
Mark Zuckerberg, the co-founder of Facebook, and his wife, the pediatrician Priscilla Chan, announced plans last month to spend $3 billion over the next decade fighting diseases. Mr. Zuckerberg and Dr. Chan said they hoped their project — including a $600-million investment in the Biohub, a new physical lab space for universities in the Bay Area — would help scientists and engineers cure, prevent, or manage all diseases by the end of the century.
Startup incubator 1776 has selected Accenture (NYSE:ACN) to provide guidance and insights to its growing roster of digital health startups.
“1776 is thrilled Accenture is with us in the mission to drive health care into the future,” said Evan Burfield, 1776 cofounder & co-CEO. “There is so much opportunity to improve health care dramatically, but it can’t be done unless talented new entrepreneurs and prestigious established institutions work closely together.”
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
